Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose study of RAY121 in healthy volunteers
jRCT2071220036Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing RAY121 arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2022; status: completed.
02
Drugs
RAY121
Beyond the preview
Go deeper on jRCT2071220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220036.